0.84
+0.19(+29.23%)
Currency In USD
Address
2450 Holcombe Boulevard
Houston, TX 77021
United States of America
Phone
832 834 6992
Sector
Healthcare
Industry
Biotechnology
Employees
2
First IPO Date
January 29, 2015
| Name | Title | Pay | Year Born |
| Frederick E. Pierce | CEO & Director | 0 | 1962 |
| Mark J. Rosenblum | Executive VP & CFO | 339,050 | 1953 |
| Barbara Hibner | Chief Scientific Officer | 0 | 1961 |
| Barb Hibner | Chief Scientific Officer | 0 | N/A |
| Michael Lipp | Chief Technology Officer | 0 | N/A |
| Nadeem Q. Mirza | Senior Vice President of Clinical Development | 0 | N/A |
| Shahin Gharakhanian | Chairman of the Scientific Advisory Board & Acting Chief Medical Officer | 0 | 1955 |
| Peter K. Marschel | Chief Business Officer | 0 | 1974 |
| Jodi Cooper | Director of Operations | 0 | N/A |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.